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Abstract: Muscarinic acetylcholine receptors (mAChRs) are prototypical Family A G protein coupled-receptors. The five mAChR sub-
types are widespread throughout the periphery and the central nervous system and, accordingly, are widely involved in a variety of both 
physiological and pathophysiological processes. There currently remains an unmet need for better therapeutic agents that can selectively 
target a given mAChR subtype to the relative exclusion of others. The main reason for the lack of such selective mAChR ligands is the 
high sequence homology within the acetylcholine-binding site (orthosteric site) across all mAChRs. However, the mAChRs possess at 
least one, and likely two, extracellular allosteric binding sites that can recognize small molecule allosteric modulators to regulate the 
binding and function of orthosteric ligands. Extensive studies of prototypical mAChR modulators, such as gallamine and alcuronium, 
have provided strong pharmacological evidence, and associated structure-activity relationships (SAR), for a “common” allosteric site on 
all five mAChRs. These studies are also supported by mutagenesis experiments implicating the second extracellular loop and the inter-
face between the third extracellular loop and the top of transmembrane domain 7 as contributing to the common allosteric site. Other 
studies are also delineating the pharmacology of a second allosteric site, recognized by compounds such as staurosporine. In addition, al-
losteric agonists, such as McN-A-343, AC-42 and N-desmethylclozapine, have also been identified. Current challenges to the field in-
clude the ability to effectively detect and validate allosteric mechanisms, and to quantify allosteric effects on binding affinity and signal-
ing efficacy to inform allosteric modulator SAR. 
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mutagenesis, radioligand binding, structure-activity studies, ternary complex model. 
INTRODUCTION 
  G protein-coupled receptors (GPCRs) account for 1 - 3% of the 
human genome, are abundantly expressed throughout the central 
nervous system (CNS) and periphery, and represent the major tar-
gets for approximately 30% of all medicines on the world market. 
However, current CNS-based GPCR drug discovery has a higher 
than average attrition rate with respect to translating fundamental 
research to the clinic [41]; this is likely due to two reasons, namely, 
an insufficient mechanistic understanding of the complexities of 
CNS GPCR-mediated signaling and a lack of selective pharmacol-
ogical tools for targeting therapeutically relevant GPCRs. As a 
consequence there are many GPCR-based drug discovery programs 
aiming to develop more selective compounds, both as tools to probe 
GPCR biology and also as potential therapeutic leads. The tradi-
tional approach to GPCR-based drug discovery has been to focus 
on targeting that region of the receptor utilized by the receptor’s 
endogenous ligand, i.e., the “orthosteric” site [80]. However, it is 
now recognized that GPCRs possess topographically distinct, allos-
teric binding sites, and that ligands that bind to these sites (allos-
teric modulators) offer tremendous potential for more selective 
and/or effective therapies than conventional orthosteric ligands. 
This brief review will focus on one of the best-studied families of 
GPCRs with respect to the phenomenon of allosteric modulation, 
namely, the muscarinic acetylcholine receptors. 
MUSCARINIC ACETYLCHOLINE RECEPTORS (mAChRs): 
A BRIEF OVERVIEW 
  The mAChRs belong to the Family A (rhodopsin-like) subclass 
of GPCRs. Pharmacological and genetic studies have identified five 
distinct mAChR subtypes, classed M1-M5. The M1, M3 and M5
subtypes preferentially couple to the Gq/11  family of G proteins, 
resulting in phospholipase C activation, hydrolysis of inositol phos-
phates and mobilization of intracellular Ca
++ stores. In contrast, the 
M2 and M4 subtypes preferentially couple to the pertussis toxin-
sensitive Gi/o  family of G proteins, resulting in the inhibition of 
adenylyl cyclase and subsequent cAMP formation. Although these 
generalizations speak to the best-characterized signaling pathways 
associated with the mAChRs, they should by no means be taken as 
absolutes. All five mAChR subtypes are known to couple pro-
miscuously to multiple G proteins, usually in a cell background 
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dependent manner, and have been linked to additional intracellular 
pathways, including activation of mitogen activated protein kinases, 
Rho GTPases, nitric oxide synthases, multiple phospholipases, and 
the modulation of a variety of potassium, calcium and chloride ion 
channels [58]. 
  The mAChRs are widely distributed throughout the periphery 
and the CNS. Activation of peripheral mAChRs leads to increases 
in exocrine secretion, contraction of cardiac and smooth muscle 
(gastrointestinal tract and lungs), and reduced heart rate. Within the 
CNS, a far more complex array of physiological behaviors is 
thought to be mediated by the mAChRs, depending on their distri-
bution and localization [13]. M1 mAChRs are predominantly ex-
pressed post-synaptically in forebrain regions including the cerebral 
cortex, hippocampus and striatum [68, 69, 76, 80, 88]. These recep-
tors have long been associated with cognitive deficits linked to 
neurodegenerative disorders, such as Alzheimer’s disease, and as 
such selective agonists of the M1 mAChR have been pursued as a 
potential avenue for treatment of dementia-related conditions [32]. 
The M2 mAChR is located pre-synaptically on both cholinergic and 
non-cholinergic neurons [30, 88] in the brainstem, hypothala-
mus/thalamus, hippocampus, striatum and cortex [68, 69, 80], and 
generally serves an inhibitory function on the release of neuro-
transmitters. It has been suggested that enhancing synaptic ACh 
levels by selectively inhibiting M2 autoreceptors may be beneficial 
in the treatment of psychosis and Alzheimer’s disease, and an at-
tractive alternative to the currently used cholinesterase inhibitors 
for the latter disorder [20]. M3 mAChRs are expressed at relatively 
low levels in a number of regions including the cortex, striatum, 
hippocampus, hypothalamus/thalamus. These receptors have been 
particularly associated with appetite regulation, and the M3 receptor 
is currently a potential target for treatment of obesity and other 
metabolic disorders [7, 34, 69, 109]. M4 mAChRs are predomi-
nantly found presynaptically in the striatum, hippocampus, cortex 
and hypothalamus/thalamus [9, 69, 80]. There is the potential that 
M4 mAChR selective antagonists may control tremor associated 
with Parkinson’s disease, whilst agonists may be developed as an-
algesics, due to the regulation of neurotransmitter release in both 
cholinergic and non-cholinergic neurons [23, 113], and as novel 
antipsychotics, due to regulation of the dopaminergic system [1, 
91]. Finally, M5 mAChRs are discretely expressed at low levels in 
the brain, in particular in the ventral tegmental area [103, 110] as 
well as co-localised with D2 dopamine receptors in the substantia 
nigra pars compacta [107]. They are also implicated in the control 
of vasodilatation of cerebral blood vessels [108]. M5 mAChRs are 
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sequent reward behaviors [111], and as such M5 selective agents 
may be used to treat addiction and psychosis, as well as maintain 
cerebral blood flow in the certain pathophysiological states such as 
cerebral ischemia.  
  The pharmacological characterization of mAChRs is not a 
straightforward task due to the high level of sequence conservation 
within the orthosteric binding site across all five mAChR subtypes. 
As a consequence, there are very few orthosteric agonists and an-
tagonists that exhibit high selectivity for one subtype to the relative 
exclusion of others. The traditional approach to pharmacological 
delineation of which mAChR governs a given response has thus 
been to use a combination of compounds, generally antagonists, to 
build up a receptor profile. For example, the M1 mAChR is gener-
ally defined as having high affinity for pirenzepine and 4-DAMP 
(4-diphenylacetoxy-N-methyl-piperidine methiodide),whilst having 
low affinity for methoctramine and himbacine. M2 mAChRs have 
high affinity for methoctramine, himbacine and AF-DX 384 (5,11-
dihydro-11-[2-[2-[(N,N-dipropylaminomethyl)piperidin-1-yl]ethyl-
amino]-carbonyl] 6H-pyrido[2,3-b][1,4]benzodiazepin-6-one) and 
have low affinity for pirenzepine and 4-DAMP. A high affinity for 
4-DAMP, and low affinity for pirenzipine, methoctramine and him-
bacine suggests the involvement of the M3 mAChR. The presence 
of the M4 mAChR can be determined using PD102807 and the 
toxin, MT3. The M5 mAChR has been notoriously difficult to iden-
tify pharmacologically, however both AF-DX 384 and AQRA741 
(11-((4-[4-(diethylamino)butyl]-1-piperidinyl)acetyl)-5,11-dihydro-
6H-pyrido(2,3-b)(1,4)benzodiazepine-6-one) have the lowest affin-
ity (at least 10 fold lower) for this subtype than any other. 
  Given the high degree of sequence homology within the 
mAChR orthosteric site, and the current paucity of suitably selec-
tive mAChR orthosteric ligands, it stands to reason that alternative 
approaches are required to better achieve target specificity. All five 
mAChRs possess at least one [25], and likely two [62], extracellular 
allosteric binding sites for small molecules, and significant efforts 
have been underway, especially within the last decade and a half, in 
trying to understand the nature of these sites. The most important 
challenge in this field remains the ability to detect and quantify the 
myriad of possible allosteric effects that can arise when two ligands 
occupy a receptor at the same time. 
DESCRIBING ALLOSTERIC INTERACTIONS 
  The binding of an allosteric ligand to its site will change the 
conformation of the receptor, which means that the “geography” of 
the orthosteric site and any other potential receptor-ligand/protein 
interfaces, can also change. As a consequence, the binding affinity 
and/or signaling efficacy of the orthosteric ligand is likely to be 
modulated, either in a positive or negative manner. The simplest 
allosteric GPCR model assumes that the binding of an allosteric 
ligand to its site modulates only the affinity of the orthosteric 
ligand; this model is referred to as the allosteric ternary complex 
model (ATCM; Fig. (1A)). Within the framework of an ATCM, the 
interaction is governed by the concentration of each ligand, the 
equilibrium dissociation constants (KA and KB, respectively) of the 
orthosteric and allosteric ligands, and the “cooperativity factor” ,
which is a measure of the magnitude and direction of the allosteric 
interaction between the two conformationally linked sites [24, 94]. 
A value of  < 1 (but greater than 0) indicates negative cooperativ-
ity, such that the binding of an allosteric ligand inhibits the binding 
of the orthosteric ligand. Values of  > 1 indicate positive coopera-
tivity, such that the allosteric modulator promotes the binding of 
orthosteric ligand, whereas values of  = 1 indicate neutral coop-
erativity, i.e. no net change in binding affinity at equilibrium. Be-
cause the two sites are conformationally linked, the allosteric inter-
action is reciprocal, i.e., the orthosteric ligand will modulate the 
binding of the allosteric ligand in the same manner and to the same 
extent.  
Fig. (1). Allosteric GPCR models. A) The simple allosteric ternary complex 
model (ATCM), which describes the interaction between an orthosteric 
ligand, A, and allosteric modulator, B, in terms of their equilibrium disso-
ciation constants (KA, KB) and the cooperativity factor, , which describes 
the magnitude and direction of the allosteric effect on ligand binding affin-
ity. B) The allosteric two state model (ATSM), which describes allosteric 
modulator effects on affinity, efficacy and the distribution of the receptor 
between active (R*) and inactive (R) states, in terms of distinct conforma-
tions selected by ligands according to their cooperativity factors for the 
different states.
  Since the simple ATCM describes the effect of the modulator 
only in terms of changes in orthosteric ligand affinity, and vice 
versa, the stimulus that is generated by the ARB ternary complex is 
assumed to be no different to that imparted by the binary AR com-
plex. In general, many mAChR modulators studied to date appear 
to behave in a manner consistent with this simple ATCM. However, 
there is no a priori reason why the conformational change engen-
dered by an allosteric modulator in the GPCR does not perturb sig-
naling efficacy in addition to, or independently of, any effects on 
orthosteric ligand binding affinity. Indeed, changes in the predomi-
nance of drug screening methods from a focus on (orthosteric) radi-
oligand binding to functional assays has unmasked modulators 
whose actions cannot be sufficiently described by the simple 
ATCM; it is clear that these latter compounds can affect the signal-
ing capacity of orthosteric agonists [75]. Moreover, there are allos-
teric ligands that not only modulate orthosteric ligand signaling, but 
also act as agonists in their own right [54]. To account for such 
allosteric effects on efficacy, the ATCM has been extended into an 
allosteric “two-state” model (ATSM; Fig. (1B)) [38]. This model 
describes GPCR function in terms of: a) the ability of the receptor 
to constitutively isomerize between active (R*) and inactive (R) 
states, as determined by the isomerization constant, L; b) the ability 
of orthosteric and allosteric ligands to modify this transition be-
tween states, i.e., to act as either agonists or inverse agonists, which 
is governed by the parameters  and ; c) the ability of each ligand 
to allosterically modulate the binding affinity of the other, governed 
by the “binding cooperativity” parameter, ; d) the ability of either 
ligand to modulate the transition to an active receptor state when 
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parameter, . While it is widely accepted that GPCRs can adopt 
multiple active and inactive conformations beyond the simple R and 
R* paradigm [102], the ATSM nonetheless provides the simplest 
mechanistic framework with which to describe the wide array of 
allosteric modulator effects on receptor binding and functional 
properties.  
  These considerations suggest that allosteric modulators can be 
furthersubdividedonthebasisoftheirphenotypic behaviors, namely, 
allosteric enhancers (of affinity, efficacy or both), allosteric an-
tagonists (affinity, efficacy or both) and allosteric agonists. It 
should also be noted that there is no reason why a modulator could 
not express more than one of these properties concomitantly, e.g., 
agonism (positive or inverse) together with enhancement or inhibi-
tion of orthosteric ligand binding/function [75, 90]. Currently, it 
remains to be determined whether a single phenotype (modulator 
only) or a combination of both modulator and agonist properties is 
the optimal approach to treating GPCR-based diseases with allos-
teric ligands. Most likely, different therapies will benefit differently 
from one type of phenotype relative to another. Irrespective of phe-
notype, the most obvious advantage of allosteric ligands is the po-
tential for greater receptor subtype selectivity, as allosteric sites 
need not have evolved to accommodate an endogenous ligand [17]. 
An additional advantage of allosteric modulators that have no ago-
nistic activity in the absence of orthosteric ligand is the ability to 
retain the spatial and temporal aspects of normal (physiological) 
receptor function; the modulator would only exert an effect when 
and where the endogenous neurotransmitter or hormone is present. 
Furthermore, modulators with limited cooperativity will have an in-
built “ceiling” level to their effect, suggesting that they may be 
potentially safer than orthosteric ligands if administered in very 
large doses.  
DETECTING ALLOSTERIC INTERACTIONS 
  By and large, cell-based functional assays have surpassed radio-
ligand binding assays as primary screens for allosteric GPCR 
modulators. However, there are advantages and disadvantages to 
both types of assays when measuring allosteric modulator effects, 
and ideally a combination of binding and functional experiments 
should be used where possible. When assessing experimental data 
for possible evidence of allosteric effects, the following approaches 
are generally utilized:  
i) Assessment of the Translocation of Orthosteric Ligand Con-
centration-Response or Binding Curves 
  Simple competition between two orthosteric ligands for a com-
mon binding site predicts a strict relationship between the apparent 
potency of one ligand in the absence relative to the presence of the 
other. This relationship is defined by the factor 1+[B]/KB, where 
[B] is the antagonist concentration, and KB its equilibrium dissocia-
tion constant [2, 33]. In functional assays this change in agonist 
potency is manifested as a progressive dextral displacement of the 
orthosteric agonist concentration-response curve; in binding assays 
this is evidenced by a complete inhibition of orthosteric radioligand 
binding by increasing concentrations of competitor, irrespective of 
the concentration of the radiolabeled probe. In contrast, because of 
the cooperativity that characterizes an allosteric interaction, the 
changes in orthosteric ligand potency in the presence of a modula-
tor can deviate dramatically from this expectation.  
  In studies of mAChRs, it is common to see the use of the high 
affinity (non-selective) radiolabeled orthosteric antagonists, [
3H]-N-
methylscopolamine ([
3H]-NMS) and [
3H]-quinuclidinyl benzilate 
([
3H]-QNB), as probes of the mAChR orthosteric site. Fig. (2)
shows the interaction between the allosteric modulators gallamine 
or alcuronium against the binding of [
3H]NMS at M2 mAChRs. In 
each instance, the allosteric interaction is evidenced by the devia-
tion of the [
3H]NMS binding isotherm from the expectations of 
simple orthosteric competition. In the case of alcuronium, the spe-
cific binding of [
3H]NMS is increased to due to a stabilization by 
the modulator of an orthosteric ligand-receptor complex character-
ized by a higher affinity of the radioligand for the receptor than  
in the absence of modulator. In the case of gallamine, specific 
[
3H]NMSbinding is reduced, but not completely; residual [
3H]NMS 
binding is still detectable, indicating that the radioligand is able to 
occupy the receptor in the presence of gallamine, albeit with sig-
nificantly reduced affinity. In addition to detecting allosteric ligands 
that modulate orthosteric ligand affinity, these types of equilibrium 
binding assays can also be used to quantify the allosteric effect in 
terms of the simple ATCM, thus providing estimates of modulator 
KB and  (Fig. 2). It should be noted, however, that for allosteric 
inhibitors with very high negative cooperativity ( approaches 
zero), the interaction may not be readily discernible from simple 
competition due to the profound reduction of radioligand affinity 
that ensues. In some cases, the allosteric nature of the interaction 
can be revealed by repeating the experiment in the presence of very 
high radioligand concentrations [57], but practical considerations 
may often preclude this approach. 
  Similar considerations apply to the measurement of allosteric 
modulator effects in functional assays. If the modulator behaves 
according to the simple ATCM, then the only effect that should be 
observed is a parallel translocation of the agonist concentration-
response curve either to the left (allosteric enhancement) or the 
right (allosteric antagonism), with no significant change in the basal 
or maximum responses (but see below). In addition, if the coopera-
tivity is limited, then the tell-tale sign of an allosteric interaction 
would be that the agonist curve translocation will approach a limit 
above which no further shifts occur, irrespective of additional in-
crements in modulator concentration. This is illustrated in Fig. 
(3A), where the prototypical allosteric modulator, gallamine, dis-
plays a progressive inability to antagonize the effects of ACh on the 
guinea pig electrically-driven left atrium as the modulator concen-
tration is increased. Often, these types of data are expressed in the 
form of a Schild regression [2], in which case the allosteric effect is 
seen as a curvilinear regression (Fig. 3B) that asymptotes towards a 
value of –Log [75]. As with binding assays, highly negative coop-
erative interactions may be difficult to distinguish from competitive 
interactions because the Schild regression will remain linear over a 
very large range of antagonist concentrations. 
ii) Assessment of the Maximum Attainable Response to an Or-
thosteric Agonist 
  The increased use of functional screening assays has certainly 
expanded the spectrum of possible allosteric effects that can be 
observed, specifically, by facilitating the detection of compounds 
Fig. (2). Interaction between the allosteric modulators gallamine or alcu-
ronium with the orthosteric radioligand, [
3H]N-methylscopolamine 
([
3H]NMS) in membranes from CHO cell stably expressing the human M2
mAChR. Curves superimposed on the data represent the best fit of the simple 
ATCM. The dashed line denotes the residual level of specific [
3H]NMS 
binding in the presence of saturating gallamine concentrations.160    Current Neuropharmacology, 2007, Vol. 5, No. 3 Gregory et al. 
that alter orthosteric ligand efficacy, as well as allosteric com-
pounds that modify receptor activity in their own right. The most 
common method of detecting an allosteric modulator that affects 
orthosteric ligand efficacy is to monitor effects on the maximal 
agonist response in the presence of increasing modulator concentra-
tions. In contrast to changes in curve translocation (agonist po-
tency), which can reflect effects on both agonist affinity and effi-
cacy, changes in maximal agonist responsiveness are more unambi-
guously attributed to modulation of agonist efficacy. Fig. (4) shows 
the interaction between the allosteric modulator, alcuronium, and 
the partial orthosteric agonist, pilocarpine, at human M2 mAChRs 
measured using a Cytosensor microphysiometer (which quantifies 
changes in whole cell extracellular acidification rates upon activa-
tion). Although the modulator is an allosteric enhancer of [
3H]NMS 
binding affinity (Fig. 2), it is clear that, when tested against pilo-
carpine, the same compound is an allosteric inhibitor of orthosteric 
agonist efficacy [112]. This is an example of the “probe-depen-
dence” of allosteric interactions, namely, that the manifestation of 
cooperativity between the orthosteric and allosteric sites is totally 
dependent on the chemical nature of the compounds occupying the 
sites; the same allosteric modulator can be negatively cooperative 
with one orthosteric ligand, and positively cooperative with an-
other. 
Fig. (4). Allosteric modulation of orthosteric agonist efficacy. Interaction 
between alcuronium and pilocarpine at human M2 mAChRs stably ex-
pressed in CHO cells. Receptor activation was quantified as a change in the 
extracellular whole cell acidification rate with a Cytosensor microphysiome-
ter.
  In practice, the ability to optimally discern an allosteric effect 
on agonist efficacy requires that the assay be performed under con-
ditions where receptor reserve and/or stimulus-response coupling 
efficiency is sufficiently low, such that the maximum effect of the 
orthosteric agonist in the absence of modulator is below the maxi-
mum possible effect attainable in the assay. Under these conditions, 
modulation of agonist efficacy will then manifest as either a reduc-
tion or an increase in the maximum observed response. In contrast, 
over-expressed or very efficiently-coupled receptor-transducer sys-
tems usually result in high degrees of signal amplification such that 
most agonists utilized behave as full agonists, i.e., yield the maxi-
mum possible cellular/tissue response. When the cellular assay 
system imposes such a ceiling, allosteric enhancement of agonist 
efficacy would only manifest as an increase in agonist potency, and 
may be misinterpreted as an allosteric effect on affinity only. Simi-
larly, allosteric inhibition of agonist efficacy in highly amplified 
signaling assays can result in progressive reductions in potency 
with no effect on agonist maximum response over the modulator 
concentration ranges examined. Although effects on agonist maxi-
mum response (with/without changes in agonist potency) can be 
used to infer allosteric modulation of efficacy, an important caveat 
to the interpretation of functional assays is that the lack of such an 
effect (with/without effects on agonist potency) cannot be used as 
evidence to rule this out, unless it is known that the system under 
investigation lacks receptor reserve. 
iii) Assessment of Orthosteric Ligand Binding Kinetics 
  Since the affinity of any ligand for its receptor is determined by 
the ratio of its association to dissociation rate constants, allosteric 
interactions that follow the simple ATCM can be detected by com-
paring the association and/or dissociation rates of a radiolabeled 
orthosteric ligand in the absence and presence of putative allosteric 
modulator. Unfortunately, the routine measurement of effects on 
association kinetics is problematic, because competitive orthosteric 
ligands will alter the “apparent” association rate simply by delaying 
the time taken for the radiolabeled probe to reach equilibrium. In 
contrast, the only way that the dissociation rate of a pre-equilibrated 
radioligand-receptor complex can be modified is if the test ligand 
binds to another site on this complex to change receptor conforma-
tion prior to the radioligand dissociating.  
  Radioligand dissociation kinetic assays thus represent a most 
useful means for detecting and validating an allosteric mode of 
action. Moreover, under certain conditions these assays can also be 
used to quantify the allosteric effect in terms of the parameters of 
the ATCM [52, 60]. Another advantage of these assays is that they 
have the potential in some cases to detect modulators with neutral 
binding cooperativity ( = 1) at equilibrium. Neutral cooperativity 
can arise as a consequence of either a lack of effect on orthosteric 
ligand association or dissociation rates or due to the modulator 
altering both properties to the same extent. If the latter mechanism 
is operative, then a dissociation kinetic assay will detect allosteric 
modulation even when an equilibrium assay will not [51]. However, 
dissociation kinetic assays are not the be-all and end-all for detect-
ing allosteric modulator effects – there are a number of situations 
where their utility is limited. The first is when the conformational 
change induced by the allosteric ligand manifests predominantly on 
orthosteric ligand association, and not dissociation; without an ap-
Fig. (3). A) Interaction between acetylcholine and gallamine at native M2 mAChRs in the guinea pig electrically-driven left atrium. Data taken from [16].  
B) Concentration-ratios (CR) were derived from the data in panel A and plotted in the form of a Schild regression. Solid curve denotes the fit of the ATCM to 
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propriately designed association kinetic assay, such a modulator 
would not be detected [62]. The second situation is for interactions 
characterized by very high negative cooperativity; under this condi-
tion, the affinity of the modulator for the radioligand-occupied re-
ceptor may be so low such that it cannot bind to perturb dissocia-
tion kinetics unless impractically high concentrations of modulator 
are utilized. A third situation where the dissociation kinetic assay 
can fail is when the conformational change mediated by the modu-
lator is manifested predominantly on effector coupling domains (i.e. 
efficacy modulation) and not on the orthosteric binding pocket. 
  The ability of certain allosteric ligands to alter dissociation of 
orthosteric ligands from the receptor also has implications for the 
design and interpretation of “equilibrium” binding studies. The time 
taken to reach equilibrium is limited by the rate of slowest dissoci-
ating ligand [78], thus at very high concentrations of an allosteric 
modulator that retards orthosteric ligand dissociation, equilibrium 
may not actually be achieved over the time course of the assay. As 
a consequence, equilibrium binding experiments may yield com-
plex modulator/radioligand interaction curves that appear inconsis-
tent with the ATCM [3, 60, 84]. In the case of allosteric enhancers, 
this kinetic artifact can result in a bell-shaped binding curve; for 
allosteric inhibitors, this can result in a biphasic inhibition curve 
[3]. 
PROTOTYPICAL ALLOSTERIC MODULATORS OF THE 
mAChRs 
  Arguably, the most comprehensively studied allosteric modula-
tors of the mAChRs are represented by neuromuscular-blocking 
agents, such as gallamine and alcuronium, and a series of alkane-
bis-onium compounds related to hexamethonium and exemplified 
by ligands such as W84 and its heptamethylene congener, C7/3-phth 
(Fig. 5). Collectively, studies with these ligands have resulted in 
extensive evidence for at least one allosteric site on all five 
mAChRs that is likely utilized by all these compounds, albeit with 
significantly different affinities [14, 28]. This will be referred to 
herein as the “common” allosteric site. 
  The earliest evidence for allosteric modulation of the mAChRs, 
and indeed of any GPCR, was obtained in isolated tissue bioassays, 
specifically, investigations of the effects of alkane-bis-onium 
modulators and, subsequently, gallamine, at native guinea pig atrial 
M2 mAChRs [19, 70]. The key finding from these early functional 
assays was that the antagonism by the modulators of orthosteric 
agonist responses approached a limit at the highest modulator con-
centrations, resulting in curvilinear Schild regressions. Importantly, 
with the subsequent widespread adoption of radioligand binding 
assays, the allosteric properties of these compounds were validated 
and further studied, confirming that their behavior is generally con-
sistent with the predictions of the simple ATCM. A seminal study 
of the effects of gallamine on M2 mAChRs by Stockton et al. [94] 
identified characteristics that have come to be associated with many 
mAChR modulators, including incomplete inhibition of specific 
[
3H]NMS binding at high modulator concentrations and a retarda-
tion of the dissociation kinetics of [
3H]NMS. Subsequent functional 
and radioligand binding studies have been extensively used to dem-
onstrate the probe-dependence of the allosteric effect, as well as the 
fact that most of these prototypical common-site modulators have 
highest affinity for the M2 mAChR and lowest affinity for the M5
mAChR [11, 12, 15, 22, 25, 39, 55, 65, 71, 72]. 
  Another significant finding in the study of mAChR allosterism 
was the identification of alcuronium as the first allosteric enhancer 
of the binding of an orthosteric mAChR ligand [84, 101]. This 
modulator acts at the same site as that recognized by gallamine and 
the alkane-bis-onium modulators [56, 85], and has proven a very 
useful tool in demonstrating the striking nature of cooperativity; at 
the M2 and M4 subtypes, alcuronium enhances [
3H]NMS binding, 
Fig. (5). Prototypical “common-allosteric site” mAChR modulators.
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whereas at the M1, M3 and M5 subtypes, it inhibits it [43]. When 
tested against different orthosteric antagonists and agonists, varying 
degrees of cooperativity are observed (mostly negative) [43, 45, 
111]. The alkaloid structure of alcuronium has also prompted inves-
tigations into related compounds, leading to the identification of 
strychnine, vincamine, eburnamonine, and brucine and its analogs 
as allosteric mAChR modulators [59, 86]. Importantly, studies on 
this series of alkaloids also resulted in the first identification of 
allosteric enhancers of agonist binding at the mAChRs [5, 45, 61]. 
Obviously, the most important agonist with respect to allosteric 
modulation is the endogenous neurotransmitter, ACh, and proof-of-
concept studies have revealed how positive, neutral and negative 
cooperativity with this agonist is possible, depending on the modu-
lator and the mAChR subtype [5, 45, 61]. Most recently, the identi-
fication of thiochrome as a selective allosteric enhancer of ACh at 
M4 mAChRs has added a new dimension to these studies, because 
the modulator binds with similar affinity at all mAChRs and 
achieves its selective effect purely from the positive cooperativity 
between itself and ACh at the M4 mAChR [64]. 
  Given that mAChR allosteric modulators can display significant 
degrees of structural diversity, it may be asked whether all these 
compounds do, indeed, bind to a common allosteric site, or whether 
they utilize different allosteric sites. The most important pharma-
cological validation of the common-site hypothesis has been de-
rived from interaction studies between different types of modula-
tors. In particular, the identification of obidoxime (Fig. 5) and d-
tubocurarine as allosteric mAChR modulators that bound with rea-
sonable affinity but exerted only a weak effect on radioligand dis-
sociation kinetics [26, 105] meant that they could be used in com-
bination with more efficacious modulators to antagonize the actions 
of the latter, as would be expected from competition for a common 
binding site [26, 96, 106].  
  The most extensive SAR studies focusing on mAChR allosteric 
modulators has thus led to the following two general categories: 
neuromuscular blockers and bis-onium modulators, and mono-
quaternaries and tertiary amines related to alkaloids; excellent re-
views on the SAR of these ligands have been published recently [6, 
77]. Other researchers in the field have also used selected members 
of these prototypical modulator families to design novel pharma-
cological tools with which to better probe the relationship between 
the common allosteric site and the orthosteric site on mAChRs. One 
important approach has been the development of [
3H]dimethyl-W84 
(Fig.  5), the first radiolabeled allosteric modulator of the M2
mAChR [97]. This compound may allow for a more direct screen-
ing of putative common-site modulators via simple competition 
binding assays [98, 99], but has also been used the validate the 
ATCM as an appropriate mechanistic descriptor of the interaction 
between the orthosteric site and prototypical common-site modula-
tors [98]. Another recent approach is the development of “hybrid” 
ligands composed of an orthosteric moiety and an allosteric moiety 
separated by an appropriate covalent linker, which can, theoreti-
cally, bind both the orthosteric and allosteric sites. The idea behind 
this approach is to utilize the allosteric site to achieve selectivity, 
while still targeting the orthosteric site for the purpose of receptor 
activation or antagonism [21, 36]. Although the interpretation of the 
mode of action of these bivalent ligands is likely to be more com-
plex than that predicted by the simple ATCM [75], the use of such 
ligands highlights but one of the many avenues available for selec-
tive mAChR targeting via exploiting the pharmacology of the pro-
totypical allosteric ligands. 
“ATYPICAL” MODULATORS OF THE mAChRs 
  In addition to the well-studied common mAChR allosteric site, 
a second site was more recently defined pharmacologically by Laz-
areno, Birdsall and colleagues [62, 63]. A number of indolocarba-
zole derivatives of staurosporine (Fig. 6), exemplified by the com-
pound, KT5720, were found to show positive, negative and neutral 
cooperativity with ACh depending on the mAChR subtype, yet did 
not appear to interact with the prototypical common-site ligands, 
gallamine and brucine [62]. The novel compounds differ from those 
reported to act at the common site, in that they generally do not 
possess a positively charged nitrogen, tend to show highest affinity 
for the M1 rather than M2 mAChR, and have little or no effect on 
[
3H]NMS dissociation rate. Similarly, analogs of the commercially 
available neurokinin receptor antagonists, WIN 62,577 and WIN 
51,708 (Fig. 6), as well as the parent compounds themselves, were 
found to interact with gallamine and strychnine in a non-
competitive manner, whilst competing with staurosporine and 
KT5720 [63]. The WIN compounds also had little or no effect on 
[
3H]NMS dissociation, with the exception of the derivative, PG987, 
which actually accelerated [
3H]NMS dissociation. A more recent 
Fig. (6). Representative “second-site” and “atypical” mAChR modulators.
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study, focusing predominantly on the M4 mAChR, found evidence 
for a negatively cooperative interaction between WIN 62,577 and 
each of C7/3-phth, alcuronium or brucine when the orthosteric site 
of the receptor was unoccupied [59]. Taken together, these findings 
indicate that a complex network of cross-interactions is attainable at 
the mAChRs. It is possible that multiple allosteric sites are also 
present on other GPCRs.  
  In addition to the “second-site” modulators described above, 
there are also a number of other allosteric ligands of the mAChRs 
that are classed as “atypical” because they exhibit pharmacological 
behaviors not consistent with the simple ATCM. These compounds 
includetacrine,thebispyridinium 4,4’-bis-[(2,6-dichloro-benzyloxy- 
imino)-methyl]-1,1’propane-1,3-diyl-bis-pyridinium dibromide (Duo 
3) and a group of pentacyclic carbazolones [35, 81, 96]. Tacrine 
(Fig. 6) is a well known anti-cholinesterase that has been reported 
to inhibit both the equilibrium binding and the dissociation kinetics 
of [
3H]NMS with slope factors significantly greater than 1 [31, 50, 
81, 82, 99]. This behavior is consistent with the expectations of 
positive homotropic cooperativity, i.e. the binding of one tacrine 
molecule promotes the binding of another [82]. However, since this 
behavior is retained in dissociation kinetic assays, where the orthos-
teric site is occupied by radioligand, the two interacting tacrine 
molecules must be utilizing two different allosteric sites, perhaps 
across a mAChR dimer. Alternatively, tacrine is small enough such 
that two molecules can conceivably bind within the “common” 
allosteric site. There are two lines of evidence to support the latter 
conclusion. First, tacrine appears to interact with the common-site 
modulators obidoxime [26] and [
3H]dimethyl-W84 [99]. Second, 
when two molecules of tacrine are covalently attached to one an-
other to form a dimeric molecule, the affinity of this dimer for the 
M2 mAChR was significantly increased, yet its interaction with 
[
3H]NMS no longer showed slope factors greater than 1 [100].  
  The bispyridinium compound Duo3 (Fig. 6) is another allosteric 
mAChR modulator [89] that displays slope factors greater than 1 
with respect to inhibition of both [
3H]NMS and [
3H]dimethyl-W84, 
as well as a non-competitive interaction with obidoxime [96, 99]. It 
has been suggested that Duo3 displays positive homotropic coop-
erativity, however, unlike tacrine, Duo3 is a large molecule and 
unlikely to be binding in multiple equivalents within a single, 
common allosteric site [100]. It is possible that Duo3 represents an 
allosteric modulator that may exert its effects across receptor di-
mers, although this remains to be determined. 
ALLOSTERIC EFFECTS ON mAChR SIGNALING AND 
OTHER BEHAVIORS 
  As outlined previously, the binding of an allosteric modulator 
induces a unique receptor conformation that has the potential to not 
only effect orthosteric ligand affinity, but also efficacy and other 
receptor behaviors; the abolition by alcuronium of pilocarpine’s 
efficacy [112; see also Fig. (4)] is one such example. In addition, 
certain allosteric ligands may promote or inhibit receptor activation 
even in the absence of agonist. Indeed, W84 has been shown to be 
an inverse agonist with respect to [
35S]GTPS binding in atrial 
membranes [40]. Alcuronium (at the M2 mAChR) and strychnine 
(at M1 and M2 subtypes) have both also been identified as inverse 
agonists with respect to [
35S]GTPS binding in recombinant expres-
sion systems [60, 112]. These findings are generally in accord with 
the expectation that if a modulator induces a receptor conformation 
that is negatively cooperative with respect to agonist binding, then 
the conformation may also predispose the receptor towards a re-
duced probability of adopting an active state. However, a study by 
Jakubik et al. (1996) [44] has found that alcuronium, gallamine, and 
strychnine were partial (positive) agonists at the M2, M4 and M1
mAChR subtypes [44]. These findings have not been reported 
elsewhere, and may reflect particular requirements with respect to 
receptor-G protein stoichiometry and the use of recombinant ex-
pression or artificial reconstitution systems [46]. 
  In recent years, there has been an increase in the number of 
reports identifying putative allosteric agonists of GPCRs. With 
respect to the mAChRs, McN-A-343 (4-(m-Chlorophenylcarba-
moyloxy)-2-butynyltrimethylammonium chloride; Fig. (7)), proba-
bly the first mAChR agonist known to display functional selectivity 
[87], was actually found to interact allosterically with [
3H]NMS in 
an equilibrium radioligand binding assay on rat atrial M2 mAChRs 
over twenty years ago [4]. An allosteric mode of interaction with 
pirenzepine had also been suggested [10], and the agonist was later 
shown to slow the dissociation kinetics of [
3H]NMS at cardiac M2
mAChRs [106]. However, this latter effect was not competitive 
with d-tubocurarine, and it was suggested that McN-A-343 may in 
fact bind in two orientations, one to the orthosteric site, and another 
to an allosteric site (Waelbroeck, 1994). When investigated in func-
tional assays [13], the interaction between carbachol and McN-A-
343 appeared consistent with simple competition, suggesting that 
McN-A-343 does indeed recognize the orthosteric site, or else dis-
plays very high negative cooperativity against ligands such as car-
bachol. The ultimate delineation of the mode of action of McN-A-
343 as both an agonist and an allosteric modulator is likely to pro-
vide novel insights into mAChR activation mechanisms. 
  A number of other agents have more recently been identified as 
potential mAChR allosteric agonists (Fig. 7); AC-42 (4-n-Butyl-1-
[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine), its analogue AC-
260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1, 
4]oxasin-3-one and N-desmethylclozapine, the major metabolite of 
the antipscyhotic clozapine. AC-42 displays unprecedented func-
tional selectivity for the M1 mAChR relative to all other subtypes, 
even though it appears to bind with similar affinity for all subtypes. 
This led to the suggestion that it recognized an “ectopic” site differ-
ent to that utilized by classic orthosteric ligands [93]. A subsequent 
study by Langmead et al. [54] provided conclusive evidence for an 
allosteric mode of action of AC-42. Specifically, the compound was 
shown to retard the dissociation of [
3H]NMS from M1 mAChRs 
and, in cell-based functional assays, the antagonism of AC-42-
mediated Ca
++ mobilization at M1 mAChRs by atropine was charac-
terized by curvilinear Schild regressions, again consistent with an 
allosteric mode of interaction [54]. Most recently, AC-260584, a 
more potent AC-42 analogue, was also shown to act allosterically at 
the M1 mAChR [92], thus highlighting that a clear SAR is likely to 
exist that defines allosteric M1 mAChR agonism. 
 Like  AC-42,  N-desmethylclozapine is a functionally-selective 
M1 mAChR agonist that has been suggested to act allosterically. 
The major lines of evidence for such a mechanism, however, are 
mainly indirect and based on mutagenesis studies that show differ-
ential effects of classic orthosteric site mutations in the M1 mAChR 
on orthosteric ligands such as carbachol, on the one hand, and func-
tionally selective agonists like AC-42 and N-desmethylclozapine, 
on the other [92, 95]. 
  In addition to acute effects on classic signaling pathways, it is 
now acknowledged that GPCR ligands can affect a far wider range 
of receptor behaviors that may have a significant impact on the 
desired therapeutic endpoint. Thus, the pharmacology of a GPCR 
ligand to impact phenomena such as receptor desensitization, phos-
phorylation and internalization may not mirror its effects in acute 
signaling assays [49]. It is of note, therefore, that a recent study 
found that prolonged exposure of CHO cells stably expressing the 
human M2 mAChR to the allosteric modulators gallamine, alcu-
ronium or C7/3-phth, resulted in a significant up-regulation of M2
mAChR expression, likely due to an alteration of receptor internali-
zation [74].  
MUTATIONAL STUDIES OF THE ALLOSTERIC SITE(S) 
  There have been two general approaches utilized to map allos-
teric binding sites on the mAChRs. The most widespread approach 
has been to use receptor chimeras or site-directed mutagenesis of 
selected amino acids of one mAChR subtype into their (non-164    Current Neuropharmacology, 2007, Vol. 5, No. 3 Gregory et al. 
conserved) counterparts of another subtype. The other approach has 
been to focus on conserved amino acids across mAChR subtypes in 
order to define residues likely to be critical to the “common” allos-
teric site at all five subtypes. To date, there have been no reported 
studies that have aimed to map the location of the “second” allos-
teric site that is utilized by staurosporine and related compounds. 
  Since most prototypical (common-site) modulators show high-
est affinity for the M2 mAChR, the bulk of structural studies of 
mAChR allosteric sites have focused on this subtype, in particular 
exploiting differences between the M2 mAChR and the M5
mAChR, since the latter generally displays lowest affinity for many 
prototypical modulators. Overall, such studies have identified roles 
for the second and third extracellular loops as well as transmem-
brane (TM) domain 7 for conferring affinity and selectivity to a 
diverse range of modulators [8, 27, 29, 37, 42, 47, 52, 67, 100, 
104],includinggallamine,alkane-bis-oniumcompounds, alcuronium 
and d-tubocurarine derivatives. For instance, early site-directed 
mutagenesis studies revealed the 
172EDGE
175 sequence, specific to 
the second extracellular loop of the M2 mAChR, to be required for 
gallamine selectivity [67]; E
172 and E
175 have been highlighted as 
particularly important, since substitution of these amino acids to 
their M1 counterparts (L and G respectively) resulted in decreased 
affinity for gallamine and W84 [42]. A tyrosine in position 177, 
also in the second extracellular loop, plays a key role in contribut-
ing to the M2 versus M5 selectivity of WDuo3 [100] and binding 
affinity for diallylcarcurine V and alkane-bis-onium compounds 
[42, 104]. N
419, at the junction between the third extracellular loop 
and TM7, plays a role in M2 versus M5 selectivity of gallamine and 
W84, although a more dominant residue appears to be the nearby 
(TM7) T
423 [8, 29, 37, 42, 104]. In terms of conserved residues, a 
tryptophan in TM7 (W
422 in the M2 mAChR) appears to be the 
dominant amino acid influencing common-site modulators [73, 83].  
  Similar studies have focused on the differences in modulator 
activities between the M3 and M2 mAChRs. Thus, introduction of 
an asparagine at position 423 of the M3 mAChR (corresponding to 
N
419 of M2 mAChR) resulted in an increase of gallamine’s affinity 
[52]) consistent with the important role that this particular amino 
acid can play in this position. In addition, N
419, V
421 and T
423 of the 
M2 mAChR were found to be important in the manifestation of 
positive cooperativity of strychnine-like modulators [47]. Collec-
tively, these mutagenesis studies, together with recent homology 
modeling based on the crystal structure of inactive state bovine 
rhodopsin [58, 83, 104], have resulted in the consensus view that 
the common allosteric binding site for the majority of prototypical 
allosteric M2 mAChR modulators is located at the opening of the 
orthosteric binding pocket, the latter which is buried further within 
the TM bundle. Fig. (8) illustrates the possible relationship between 
key residues of the orthosteric and allosteric pocket on the M2
mAChR, based on homology to bovine rhodopsin. 
Fig. (8). Schematic representation of the relationship between residues 
comprising the orthosteric and “common” allosteric site on the M2 mAChR, 
using a homology model based on the crystal structure of inactive state 
bovine rhodopsin. Regions highlighted in blue incorporate the following 
orthosteric-site residues: W
99, D
103, S
107, Y
110, W
155, T
187, T
190, W
400, Y
403,
N
404, Y
426, Y
430. Regions highlighted in purple incorporate the following 
allosteric site residues: 
172EDGE
175, Y
177, N
419, N
422, N
423. The residues in 
yellow represent a cysteine pair, and corresponding disulphide bond be-
tween the second extracellular loop and top of TM3, that are highly con-
served in over 90% of GPCRs.
  In contrast to the prototypical modulators, the binding of puta-
tive allosteric agonists is believed to be via mAChR epitopes dis-
tinct from both the orthosteric and common allosteric sites [92, 93, 
95], although it should be noted that it is far more difficult to inter-
pret the results of mutagenesis studies on agonists because the mu-
tations can affect not only binding affinity, but efficacy as well. 
Initial studies aimed at investigating the high degree of functional 
selectivity of AC-42 for the M1 mAChR utilized M1/M5 chimeras, 
and suggested roles for the N-terminus/TM1 and third extracellular 
loop/TM7 in AC-42 agonism [93]. Additionally, mutagenesis of 
Y
381, a key orthosteric site residue in TM6, to Ala of the M1
mAChR led to a dramatic reduction in the affinity and potency of 
carbachol, but had no effect on AC-42 [93]. Interestingly, this same 
mutation actually led to an increase in the agonistic activity of N-
desmethylclozapine [95], clearly indicating that the latter agonist 
utilizes a different mode of attachment to classic orthosteric 
ligands, such as carbachol. A more recent study investigating muta-
tions in TM3 known to contribute to the orthosteric site, and which 
dramatically reduce the efficacy and/or potency of carbachol, found 
Fig. (7). Putative allosteric mAChR agonists.
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varied effects on the AC-42, AC-260584 and N-desmethylclozapine 
[92]. Specifically, a W
101A substitution increased AC-42 and 
AC260584 potency and efficacy but had no effect on N-desmethyl-
clozapine.Mutationof Y
106A increased the efficacy of N-desmethyl-
clozapine, whilst S
109A increased AC-42, AC-260584 and N-
desmethylclozapine potency [92].  
CONCLUSION 
  Allosteric modulation of GPCRs represents an exciting and 
growing field of research, both with respect to drug discovery and a 
better understanding of GPCR structure and function. The mAChRs 
remain one of the key model systems for investigating this phe-
nomenon at Family A GPCRs. Not only are there now a good num-
ber of structurally diverse allosteric modulators identified for this 
receptor family, but the receptors themselves remain important 
therapeutic candidates that have yet to be optimally targeted, thus 
ensuring an impetus for additional exploration of allosteric ligand 
chemical space. As with many nascent fields, however, significant 
challenges remain. The prevalence and relevance of allosteric ago-
nists of the mAChRs, for example, has not been fully gauged as yet. 
Mutagenesis and molecular modeling studies aimed at mapping 
putative allosteric sites, with a view towards relating structure to 
function and identifying novel ligands, still have much ground to 
cover. Nonetheless, the potential rewards are significant and, as 
such, the study of mAChR allosterism remains one that is likely to 
deliver significant pharmacological dividends. 
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